ABSTRACT
Photodynamic therapy is a treatment that uses photosensitizer and intense visible light. When photosensitizers get exposed to a specific light wavelength [preferentially in the red region], they produce reactive oxygen species that are toxic to cells. Recently, attention has been focused on porphyrins and their analogs as photosensitizers. Zn [II] tetrapyridinoporphyrazin complex is a water-soluble photosensitizer that has a good potential for application in photodynamic therapy. In this study, phototoxic effect of this complex on HeLa cancer cell line has been investigated. HeLa cell cultures were treated with different concentrations of Zn [II] tetrapyridinoporphyrazin. The cytotoxic effects were measured both in the presence and absence of light using the MTT assay. The light source was a 150W tungsten halogen lamp equipped with a red filter. Our data indicate that porphyrazine's photocytotoxicity is remarkably more significant than its cytotoxycity in the dark. Statistical analysis showed the effective dose [ED[50]] values in the dark and light conditions were 8.6 and 4.2 microM, respectively. In addition, the results imply that in the range of 0-12 microM, the increase in the complex concentration correlates with the increase in the cytotoxicity effect. However, the cytotoxicity decreases at the higher concentration [50microM], which is likely due to aggregation of the complex. Our results show that Zn [II] tetrapyridinoporphyrazin complex may be a promising photosensitizer for innovative photodynamic therapy and may have a high potential application in cancer treatment. Furthermore, it seems to have more benefits compared to other known photosensitizers
ABSTRACT
Glioma is the most common primary brain tumor. Despite many advances in treatment, all patients die within 6 to 18 months after diagnosis. In the cases of glioma, the immune system is suppressed in a local fashion. Therefore, unveiling the cellular and molecular mechanisms involved, with the aim of obtaining an appropriate new treatment is a priority. Designing an appropriate animal model is necessary before any clinical trials. In this study, we prepared fifteen 6-8 week-old female mice [Balb/C] from the Pasteur institute, Tehran, and also selected the mouse glioma cell line GL26 to induce a allogeneic subcutaneous tumor. After culturing the cell and anesthetization of the mice, we injected different cell doses into distinct groups of mice. Sterile PBS was injected into the control group. Animal behavior and clinical symptoms were regularly followed and recorded, and after tumor induction, it was surgically removed and evaluated in terms of macroscopic and microscopic characteristics. The tumor was induced more quickly with higher number of GL26 cells in mice. Atrophy and weakness was observed in the affected animals. In macroscopic examination, the tumor was relatively large, thick and full of blood. Moreover, in microscopic examination, cell proliferation, mitosis, abundant vessels, and tumor necrosis were observed. Regarding the limitations of a glioma syngeneic animal model, establishment of an allogeneic subcutaneous model, allows an easy evaluation of the size and volume of the tumor, without a requirement for sacrificing the animal. This model has the potential to provide opportunities for research on some immunological parameters, the testing of new therapeutic agents, and new discoveries in basic research, concerning glioma, for the first time in Iran